Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025)

Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective c...

Descripción completa

Detalles Bibliográficos
Autores principales: Softic, Laurent, Brillet, Rozenn, Berry, François, Ahnou, Nazim, Nevers, Quentin, Morin-Dewaele, Margot, Hamadat, Sabah, Bruscella, Patrice, Fourati, Slim, Pawlotsky, Jean-Michel, Ahmed-Belkacem, Abdelhakim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318051/
https://www.ncbi.nlm.nih.gov/pubmed/32376613
http://dx.doi.org/10.1128/AAC.00876-20
Descripción
Sumario:Cyclophilins play a key role in the life cycle of coronaviruses. Alisporivir (Debio 025) is a nonimmunosuppressive analogue of cyclosporine with potent cyclophilin inhibition properties. Alisporivir reduced SARS-CoV-2 RNA production in a dose-dependent manner in Vero E6 cells, with a 50% effective concentration (EC(50)) of 0.46 ± 0.04 μM. Alisporivir inhibited a postentry step of the SARS-CoV-2 life cycle. These results justify rapidly conducting a proof-of-concept phase 2 trial with alisporivir in patients with SARS-CoV-2 infection.

Ejemplares similares